MARK CABAHUG: Open Payments
NPI 1922455898 · MORRISTOWN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$586 in 21 payments from 9 companies in 2025. Trend: 2023 $607 · 2024 $739 · 2025 $586
Food & beverage: $586
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 6 | $133 |
| AstraZeneca Pharmaceuticals LP | 4 | $119 |
| ABIOMED | 1 | $104 |
| Novartis Pharmaceuticals Corporation | 3 | $67 |
| Actelion Pharmaceuticals US, Inc. | 2 | $61 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 2 | $33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $28 |
| Novo Nordisk Inc | 1 | $25 |
| PFIZER INC. | 1 | $15 |
Products named: LOKELMA, LEQVIO, Repatha, FARXIGA, OPSUMIT, LifeVest, JARDIANCE, OPSYNVI.
Industry payments across NJ — which companies pay providers there.
